Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse

Documenti analoghi

• Clinical Relevance and Prognostic Value of the Triple A ( AAA ) Score in Patients With Myelofibrosis ( MF ) Treated With Ruxolitinib ( RUX )
  di: Alessandro Laganà, et al.
  Pubblicazione: (2025)
• Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study
  di: Alessandro Costa, et al.
  Pubblicazione: (2026)
• Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
  di: Alessandro Laganà, et al.
  Pubblicazione: (2024)
• Chronic eosinophilic leukaemia—Not otherwise specified: Clinical features, genomic insight and therapeutic strategies
  di: Alessandro Costa, et al.
  Pubblicazione: (2024)
• Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions
  di: Antonella Bruzzese, et al.
  Pubblicazione: (2025)